- Home
- ACRV vs FBIO Comparison
ACRV vs FBIO Comparison
Compare ACRV & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- FBIO
- Stock Information
- Founded
- ACRV 2018
- FBIO 2006
- Country
- ACRV United States
- FBIO United States
- Employees
- ACRV N/A
- FBIO N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- FBIO Health Care
- Exchange
- ACRV Nasdaq
- FBIO Nasdaq
- Market Cap
- ACRV 59.9M
- FBIO 49.1M
- IPO Year
- ACRV 2022
- FBIO N/A
- Fundamental
- Price
- ACRV $1.16
- FBIO $1.69
- Analyst Decision
- ACRV Strong Buy
- FBIO Strong Buy
- Analyst Count
- ACRV 5
- FBIO 3
- Target Price
- ACRV $19.75
- FBIO $21.00
- AVG Volume (30 Days)
- ACRV 1.3M
- FBIO 144.5K
- Earning Date
- ACRV 05-20-2025
- FBIO 05-19-2025
- Dividend Yield
- ACRV N/A
- FBIO N/A
- EPS Growth
- ACRV N/A
- FBIO N/A
- EPS
- ACRV N/A
- FBIO N/A
- Revenue
- ACRV N/A
- FBIO $57,675,000.00
- Revenue This Year
- ACRV N/A
- FBIO $63.20
- Revenue Next Year
- ACRV N/A
- FBIO $66.70
- P/E Ratio
- ACRV N/A
- FBIO N/A
- Revenue Growth
- ACRV N/A
- FBIO N/A
- 52 Week Low
- ACRV $1.30
- FBIO $1.33
- 52 Week High
- ACRV $10.29
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- ACRV 28.93
- FBIO 52.97
- Support Level
- ACRV $1.32
- FBIO $1.67
- Resistance Level
- ACRV $1.50
- FBIO $1.84
- Average True Range (ATR)
- ACRV 0.17
- FBIO 0.09
- MACD
- ACRV 0.06
- FBIO 0.01
- Stochastic Oscillator
- ACRV 1.55
- FBIO 58.54
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.